<DOC>
	<DOCNO>NCT02260193</DOCNO>
	<brief_summary>The purpose study evaluate hemoglobin response ( efficacy ) , safety , tolerability orally administer AKB-6548 subject end stage renal disease undergo chronic hemodialysis .</brief_summary>
	<brief_title>16-Week Repeat Oral Dose Study AKB-6548 Anemia Subjects With End Stage Renal Disease ( ESRD ) Requiring Chronic Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Key 18 79 year inclusive Chronic Kidney Disease ( CKD ) Stage 5 chronic hemodialysis least 3 month Anemia secondary CKD treat erythropoiesis stimulating agent intravenous iron Key BMI &gt; 44.0 kg/m2 Transfusion within 8 week prior Screening ALT total bilirubin &gt; 1.25x ULN Uncontrolled hypertension Class III IV congestive heart failure Myocardial infarction , acute coronary syndrome , stroke transient ischemic attack within 6 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>anemia</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>dialysis</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor propyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>